ClinicalTrials.gg
RecruitingNCT05505019Updated Mar 23, 2026

Targeting Apathy With Music in Parkinson's Disease

An interventional study of Music listening and Podcast listening in Parkinson Disease and Apathy, sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by University of British Columbia · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Feb 2022, registered Jul 2022).
  • Started Feb 2022; still recruiting 4 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Parkinson Disease by University of British Columbia — 7 open to participants now, 9 under way, none of them phase 3. Parkinson Disease · University of British Columbia.

Planned enrollment
6th of 13
50 · median 40
Started
2022
the only one that year
No phase
10 of 14
5 open now
Registered
7th of 14
by date

Among the 14 studies in Parkinson Disease by University of British Columbia, this one is the 6th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2022, is one of 10 with no phase, and was the 7th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

7 of the 14 studies in Parkinson Disease by University of British Columbia are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Parkinson Disease by University of British Columbia, or all of them as a file.
02

Study summary

Parkinson's Disease (PD) is often accompanied by non-motor symptoms that make treatment more difficult. One such symptom is apathy (lack of motivation and emotion). There are no treatments for apathy in PD, and this remains a major unmet need in PD patients. One possible way to target apathy in PD patients is listening to music, which has been shown to help improve apathy in older adults. Little work has explored the mechanism in which music targets apathy. Thus, the goal of this study is to understand how music listening can impact the brain towards decreasing apathy in PD patients.

Read the detailed description

Apathy is a common neuropsychiatric disturbance that manifests in approximately a quarter of patients in early stages of Parkinson's Disease (PD) and becomes more prevalent over disease progression and cognitive decline. Apathy in PD has been categorized as a distinct behavioural syndrome which can be differentiated from depression and anxiety, and is independently associated with lower functioning in daily life, decreased treatment response, and worse quality of life compared with PD patients without apathy. Characterized by a dysfunction in motivation, or lack of self-initiated goal-directed actions, apathy in PD has been hypothesized to stem from dysfunction in goal-directed reward-seeking networks that rely on dopaminergic transmission in the mesocorticolimbic and frontostriatal pathways, which includes the striatum (includes the nucleus accumbens, or NAc), prefrontal cortex (PFC), hippocampus, and amygdala. Pharmacological trials have attempted to target apathy through the neurotransmitter systems with limited success and sometimes adverse effects. The treatment of apathy remains a major unmet need in PD; thus, it is crucial to develop therapeutic interventions targeting apathy in PD and better understand the underlying mechanisms that may lead to apathy.

Evidence of the positive effects of music-based interventions (MBIs) in both healthy aging and clinical geriatric populations has been examined extensively across the literature. The positive effects of MBIs on alleviating apathy and increasing motivation have been reported in studies focusing on several clinical populations, such as dementia, autism spectrum disorder, and patients undergoing cardiac rehabilitation. A major gap in the MBI clinical trials literature is the lack of attention on the underlying mechanisms in which music can carry out its effects, especially regarding reward pathways. Dysfunction in the reward pathways, which involve the striatum, limbic system, and prefrontal cortices, underlie many disorders, symptoms, and syndromes, and elucidating the role of this underlying network with music is important towards understanding how music can mediate reward deficiencies, such as apathy. Understanding how music works to improve brain functioning is a key gap in understanding how to best inform the development of new therapies and interventions.

Recent work in functional, neurochemical, and pharmacological studies have helped elucidate the role of music in activating reward pathways. Namely, the nucleus accumbens (NAc) has been shown to be involved with processing peak emotionally arousing musical experiences, such as the "chills", and subjective valuations from music. Dopamine transmission in the ventral and dorsal striatum is implicated in regulating this process determined through positron emission tomography (PET) imaging. This work has established the role that the NAc and striatum, and dopaminergic transmission play in processing reward from music and its effects on aspects of cognition, such as motivation, learning, and memory. Thus, the effects of music may be able to mediate the underlying reward system that is compromised in PD patients.

More recently, connectivity between reward and auditory circuits, which include the superior temporal gyrus (STG), superior temporal sulcus (STS) and Heschl's gyrus (HG), have been implicated in musical reward processing and evaluation. No studies to date have observed the immediate and long-term effects of rewarding music on the implicated auditory-reward circuitry and action-oriented behaviour. Thus, this study aims to examine the immediate and longitudinal effects of participant-evaluated rewarding music on clinical apathy measures, connectivity in the auditory-reward networks, and effortful activity in PD patients with and without apathy.

03

Conditions studied

  • Parkinson Disease
  • Apathy

Browse trials for

Keywords

  • Music
  • Music intervention
  • Non-motor symptoms
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Clinical diagnosis of Parkinson's Disease following MDS Parkinson's disease criteria

Exclusion criteria

Exclusion Criteria:

  • Participants with atypical Parkinsonism (eg. Progressive supranuclear palsy, multiple system atrophy, drug induced, etc.)
  • Epilepsy
  • Other neurological disease/complications (eg. myopathy, stroke, brain lesion, MS)
  • Significant cognitive impairment (MoCa \<21)
  • Moderate depression (Beck's Depression Inventory >20)
  • Severe/multiple head trauma(s)
  • Participants with metal/medical implants, including any of the following: artificial heart valve, brain aneurysm clip, electrical stimulators, ear or eye implant, implanted drug infusion pump, coil, catheter, or filter in any blood vessel, orthopedic hardware such as artificial joint, plate, and/or screws, other metallic prostheses, shrapnel, bullets, or other metal fragments, surgery or tattoos, including tattooed eyeliner, in the last six weeks, cardiac pacemaker, wires or defibrillator, or ferromagnetic aneurysm clip)
  • Participants who have gone through specific injuries/brain surgery (eg. an injury where a piece of metal lodged in the eye or orbit)
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Parkinson's Disease with apathy - Music-listening

    Participants in this arm will receive a YouTube account app to use. Prior to the start of the intervention, a research team member will guide participants in this group in constructing a playlist of music that they "find rewarding or motivating".

    Other: Music listening

  • Experimental
    Parkinson's Disease with apathy - Podcast-listening

    Participants in this arm will receive a YouTube account app to use. Prior to the start of the intervention, a research team member will guide participants in this group in choosing a podcast that they "find rewarding or motivating".

    Other: Podcast listening

Interventions

  • OtherMusic listening

    This intervention involves listening to participant-selected music that they have evaluated as rewarding/motivating. YouTube Music will be used to build both personalized music and podcast interventions.

  • OtherPodcast listening

    This intervention involves listening to participant-selected podcasts of neutral content. YouTube Music will be used to build both personalized music and podcast interventions.

06

What researchers measure

Primary outcomes

  1. Change in seed-based functional connectivity between auditory, reward, and motor areas (implicated in musical reward processing) during a music-listening task, before and after an 8-week audio-based intervention

    fMRI - task-based functional magnetic resonance imaging

    Time frame: 8 weeks

  2. Change in seed-based functional connectivity between auditory, reward, and motor areas (implicated in musical reward processing) at rest, before and after an 8-week audio-based intervention

    rsfMRI - resting state functional magnetic resonance imaging

    Time frame: 8 weeks

  3. Change in univariate whole-brain analysis at rest before and after an 8-week audio-based intervention

    rsfMRI - resting state functional magnetic resonance imaging; observing activity across the brain and in specific regions of interest (ROIs), including reward, auditory, and motor areas

    Time frame: 8 weeks

  4. Change in univariate whole-brain analysis during a music listening task before and after an 8-week audio-based intervention

    fMRI - task-based functional magnetic resonance imaging; observing activity across the brain and in specific regions of interest (ROIs), including reward, auditory, and motor areas

    Time frame: 8 weeks

  5. Change in fMRI representational similarity analysis during a music listening task before and after an 8-week audio-based intervention

    fMRI - task-based functional magnetic resonance imaging; observing correlated BOLD (blood oxygen level dependent) activity across the brain and in specific regions of interest (ROIs), including reward, auditory, and motor areas

    Time frame: 8 weeks

  6. Change in fMRI representational similarity analysis at rest before and after an 8-week audio-based intervention

    rsfMRI - resting state functional magnetic resonance imaging; observing correlated BOLD (blood oxygen level dependent) activity across the brain and in specific regions of interest (ROIs), including reward, auditory, and motor areas

    Time frame: 8 weeks

  7. Short-term clinical measure of apathy before and after an 8-week audio-based intervention -Positive and Negative Affective Schedule (PANAS)

    The PANAS is a self-reported 20-item scale with 2 major subscales: Positive affect score and Negative affect score. Items are scored on a scale of 1-5. Scores range from 10-50 for both the Positive and Negative Affect, with higher scores representing higher levels of Positive/Negative affect.

    Time frame: 8 weeks

  8. Short-term clinical measure of apathy after a 4-week washout period post-intervention - Positive and Negative Affective Schedule (PANAS)

    The PANAS is a self-reported 20-item scale with 2 major subscales: Positive affect score and Negative affect score. Items are scored on a scale of 1-5. Scores range from 10-50 for both the Positive and Negative Affect, with higher scores representing higher levels of Positive/Negative affect.

    Time frame: 4 weeks

  9. Short-term clinical measure of apathy before and after an 8-week audio-based intervention - Visual Analogue Scale (VAS)

    The VAS is a visual scale with a rating from 1-10; participants are to indicate the level of apathy and motivation felt at their current state. Higher values indicate more severe apathy.

    Time frame: 8 weeks

  10. Short-term clinical measure of apathy after a 4-week washout period post-intervention - Visual Analogue Scale (VAS)

    The VAS is a visual scale with a rating from 1-10; participants are to indicate the level of apathy and motivation felt at their current state. Higher values indicate more severe apathy.

    Time frame: 4 weeks

  11. Long-term clinical measure of apathy before and after an 8-week audio-based intervention - Starkstein Apathy Scale (SAS)

    The SAS is a 14-item clinical scale used to evaluate apathy in clinical populations. Higher scores indicate more severe apathy. Scores range from 0-42. Participants who score \>=14 are considered as having clinical apathy.

    Time frame: 8 weeks

  12. Long-term clinical measure of apathy after a 4-week washout period post-intervention - Starkstein Apathy Scale (SAS)

    The SAS is a 14-item clinical scale used to evaluate apathy in clinical populations. Higher scores indicate more severe apathy. Scores range from 0-42. Participants who score \>=14 are considered as having clinical apathy.

    Time frame: 4 weeks

  13. Clinical assessment of apathy before and after an 8-week audio-based intervention - Lille Apathy Rating Scale (LARS)

    The LARS is a 33-item assessment with 9 subscales: everyday productivity, interests, taking the initiative, novelty seeking, motivation - voluntary actions, emotional responses, concern, social life, and self-awareness. There is a mix of open-ended (items scored between -2 and 2) and multiple choice items (items scored between -1 and 1). Scores range from -36 to 36. Higher scores indicate more severe apathy.

    Time frame: 8 weeks

  14. Clinical assessment of apathy after a 4-week washout period post-intervention - Lille Apathy Rating Scale (LARS)

    The LARS is a 33-item assessment with 9 subscales: everyday productivity, interests, taking the initiative, novelty seeking, motivation - voluntary actions, emotional responses, concern, social life, and self-awareness. There is a mix of open-ended (items scored between -2 and 2) and multiple choice items (items scored between -1 and 1). Scores range from -36 to 36. Higher scores indicate more severe apathy.

    Time frame: 4 weeks

  15. Clinical assessment of apathy in Parkinson's Disease before and after an 8-week audio-based intervention - Movement Disorders Society Unified Parkinson's Disease Rating Scale - apathy item (MDS-UPDRS)

    The MDS-UPDRS is a clinical assessment of motor and non-motor symptoms in individuals with Parkinson's Disease. It consists of four subscales. Subscales 1, 3, and 4 are administered by a trained individual with subscale 2 being self reported. Each item is rated from 0 to 4.

    Time frame: 8 weeks

  16. Clinical assessment of apathy in Parkinson's Disease after a 4-week washout period post-intervention - Movement Disorders Society Unified Parkinson's Disease Rating Scale - apathy item

    The MDS-UPDRS is a clinical assessment of motor and non-motor symptoms in individuals with Parkinson's Disease. It consists of four subscales. Subscales 1, 3, and 4 are administered by a trained individual with subscale 2 being self reported. Each item is rated from 0 to 4.

    Time frame: 4 weeks

  17. Assessment of musical reward sensitivity before and after an 8-week audio-based intervention - Barcelona Musical Reward Questionnaire (BMRQ)

    The BMRQ is a validated 20-item assessment of musical reward sensitivity (how responsive a participant is to the rewarding effects of music listening). It has 5 subscales: musical seeking, emotion evocation, mood regulation, social reward, and sensory-motor. Items are scored from 1-5. Higher scores indicate higher sensitivity to reward.

    Time frame: 8 weeks

  18. Assessment of musical reward sensitivity after a 4-week washout period post-intervention - Barcelona Musical Reward Questionnaire (BMRQ)

    The BMRQ is a validated 20-item assessment of musical reward sensitivity (how responsive a participant is to the rewarding effects of music listening). It has 5 subscales: musical seeking, emotion evocation, mood regulation, social reward, and sensory-motor. Items are scored from 1-5. Higher scores indicate higher sensitivity to reward.

    Time frame: 4 weeks

  19. Grip force response (GFR) during a music listening fMRI task before and after an 8-week audio-based intervention

    GFR is a physical effort measure; it is a validated measure of apathy in Parkinson's Disease (Zhu et al., 2021)

    Time frame: 8 weeks

  20. Grip force duration and fatigue during a music listening fMRI task before and after an 8-week audio-based intervention

    Grip force duration and fatigue are physical effort measures; they are validated measures of apathy in Parkinson's Disease (Zhu et al., 2021)

    Time frame: 8 weeks

Secondary outcomes

  1. Clinical assessment for Quality of Life before and after an 8-week audio-based intervention - Quality of Life Scale (QOLS); observing if the intervention improves QoL measures

    Quality of Life Scale (QOLS)

    Time frame: 8 weeks

  2. White and grey matter distribution

    T1-weighted magnetic resonance image (MRI)

    Time frame: 8 weeks

Other outcomes

  1. Clinical assessment for overall cognition - Montreal Cognitive Assessment (MoCA)

    The MoCA is a researcher-administered 30-item assessment covering 8 aspects of cognition: visuospatial/executive, naming, memory, attention, language, abstraction, delayed recall, and orientation. Scores range from 0-30. Higher scores indicate better cognition; lower scores indicate poorer cognition.

    Time frame: 0 weeks (baseline)

  2. Clinical assessment for depressive symptoms (not diagnostic) - Beck's Depression Inventory (BDI)

    The BDI is a self reported 21-question multiple-choice self-report inventory on a scale from 0-3. Scores range from 0-63. Higher scores indicate higher levels of depression; scores over 40 are considered as extreme depression. It will be used as a screening tool to observe any overlap between apathy and depression.

    Time frame: 0 weeks (baseline)

  3. Validated assessment of musical perception (contour subtest) - Montreal Battery of Evaluation of Amusia (MBEA);

    The Montreal Battery of Evaluation of Amusia (MBEA) measures level of general music perception for universal musical structures. This will be used to rule out any non-effects of the music intervention due to a deficit in musical perception abilities; the contour subtest will be used to evaluate this.

    Time frame: 0 weeks (baseline)

  4. Clinical assessment of overall reward/pleasure sensitivity - Snaith-Hamilton Pleasure Scale (SHAPS)

    The SHAPS will be used to compare with BMRQ to isolate for overall anhedonia/apathy versus music-specific apathy (Loui and Belfi, 2020). Higher scores correlate with higher apathy/less pleasure.

    Time frame: 0 weeks (baseline)

  5. White matter tract - axial diffusivity; lesion analysis in white matter tracts (focus on arcuate fasciculus)

    diffuse tensor image (DTI)

    Time frame: 8 weeks

  6. White matter tracts; lesion analysis in white matter tracts (focus on arcuate fasciculus)

    diffuse tensor image (DTI)

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
  • Djavad Mowafghian Centre for Brain Health
    Vancouver, British Columbia V6T1Z3, Canada
    Recruiting
08

References and documents

Publications

  • Pagonabarraga J, Kulisevsky J. Apathy in Parkinson's Disease. Int Rev Neurobiol. 2017;133:657-678. doi: 10.1016/bs.irn.2017.05.025. Epub 2017 Jul 10. PubMed 28802937 ↗
  • Pagonabarraga J, Kulisevsky J, Strafella AP, Krack P. Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol. 2015 May;14(5):518-31. doi: 10.1016/S1474-4422(15)00019-8. Epub 2015 Apr 12. PubMed 25895932 ↗
  • Aarsland D, Bronnick K, Alves G, Tysnes OB, Pedersen KF, Ehrt U, Larsen JP. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. J Neurol Neurosurg Psychiatry. 2009 Aug;80(8):928-30. doi: 10.1136/jnnp.2008.166959. PubMed 19608786 ↗
  • Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, Bottacchi E, Cannas A, Ceravolo G, Ceravolo R, Cicarelli G, Gaglio RM, Giglia RM, Iemolo F, Manfredi M, Meco G, Nicoletti A, Pederzoli M, Petrone A, Pisani A, Pontieri FE, Quatrale R, Ramat S, Scala R, Volpe G, Zappulla S, Bentivoglio AR, Stocchi F, Trianni G, Dotto PD; PRIAMO study group. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord. 2009 Aug 15;24(11):1641-9. doi: 10.1002/mds.22643. PubMed 19514014 ↗
  • Golebiowski D, van der Bom IMJ, Kwon CS, Miller AD, Petrosky K, Bradbury AM, Maitland S, Kuhn AL, Bishop N, Curran E, Silva N, GuhaSarkar D, Westmoreland SV, Martin DR, Gounis MJ, Asaad WF, Sena-Esteves M. Direct Intracranial Injection of AAVrh8 Encoding Monkey beta-N-Acetylhexosaminidase Causes Neurotoxicity in the Primate Brain. Hum Gene Ther. 2017 Jun;28(6):510-522. doi: 10.1089/hum.2016.109. Epub 2017 Jan 26. PubMed 28132521 ↗
  • Marin RS. Apathy: Concept, Syndrome, Neural Mechanisms, and Treatment. Semin Clin Neuropsychiatry. 1996 Oct;1(4):304-314. doi: 10.1053/SCNP00100304. PubMed 10320433 ↗
  • Schmidt L, d'Arc BF, Lafargue G, Galanaud D, Czernecki V, Grabli D, Schupbach M, Hartmann A, Levy R, Dubois B, Pessiglione M. Disconnecting force from money: effects of basal ganglia damage on incentive motivation. Brain. 2008 May;131(Pt 5):1303-10. doi: 10.1093/brain/awn045. Epub 2008 Mar 15. PubMed 18344560 ↗
  • Chatterjee A, Fahn S. Methylphenidate treats apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2002 Fall;14(4):461-2. doi: 10.1176/jnp.14.4.461. No abstract available. PubMed 12426416 ↗
  • Zahodne LB, Bernal-Pacheco O, Bowers D, Ward H, Oyama G, Limotai N, Velez-Lago F, Rodriguez RL, Malaty I, McFarland NR, Okun MS. Are selective serotonin reuptake inhibitors associated with greater apathy in Parkinson's disease? J Neuropsychiatry Clin Neurosci. 2012 Summer;24(3):326-30. doi: 10.1176/appi.neuropsych.11090210. PubMed 23037646 ↗
  • Lam HL, Li WTV, Laher I, Wong RY. Effects of Music Therapy on Patients with Dementia-A Systematic Review. Geriatrics (Basel). 2020 Sep 25;5(4):62. doi: 10.3390/geriatrics5040062. PubMed 32992767 ↗
  • Tsoi KKF, Chan JYC, Ng YM, Lee MMY, Kwok TCY, Wong SYS. Receptive Music Therapy Is More Effective than Interactive Music Therapy to Relieve Behavioral and Psychological Symptoms of Dementia: A Systematic Review and Meta-Analysis. J Am Med Dir Assoc. 2018 Jul;19(7):568-576.e3. doi: 10.1016/j.jamda.2017.12.009. Epub 2018 Feb 1. PubMed 29396186 ↗
  • Tang Q, Zhou Y, Yang S, Thomas WKS, Smith GD, Yang Z, Yuan L, Chung JW. Effect of music intervention on apathy in nursing home residents with dementia. Geriatr Nurs. 2018 Jul-Aug;39(4):471-476. doi: 10.1016/j.gerinurse.2018.02.003. Epub 2018 Mar 15. PubMed 29551546 ↗
  • Goris ED, Ansel KN, Schutte DL. Quantitative systematic review of the effects of non-pharmacological interventions on reducing apathy in persons with dementia. J Adv Nurs. 2016 Nov;72(11):2612-2628. doi: 10.1111/jan.13026. Epub 2016 Jun 23. PubMed 27221007 ↗
  • Quintin EM. Music-Evoked Reward and Emotion: Relative Strengths and Response to Intervention of People With ASD. Front Neural Circuits. 2019 Sep 18;13:49. doi: 10.3389/fncir.2019.00049. eCollection 2019. PubMed 31619969 ↗
  • Bowles L, Curtis J, Davies C, Lengerich A, Bugajski A. The effect of music on mood, motivation, and exercise among patients in a cardiac rehabilitation program: A pilot study. Nurs Forum. 2019 Jul;54(3):340-344. doi: 10.1111/nuf.12334. Epub 2019 Feb 25. PubMed 30802308 ↗
  • Le Heron C, Holroyd CB, Salamone J, Husain M. Brain mechanisms underlying apathy. J Neurol Neurosurg Psychiatry. 2019 Mar;90(3):302-312. doi: 10.1136/jnnp-2018-318265. Epub 2018 Oct 26. PubMed 30366958 ↗
  • Volkow ND, Michaelides M, Baler R. The Neuroscience of Drug Reward and Addiction. Physiol Rev. 2019 Oct 1;99(4):2115-2140. doi: 10.1152/physrev.00014.2018. PubMed 31507244 ↗
  • Adam TC, Epel ES. Stress, eating and the reward system. Physiol Behav. 2007 Jul 24;91(4):449-58. doi: 10.1016/j.physbeh.2007.04.011. Epub 2007 Apr 14. PubMed 17543357 ↗
  • Martin-Soelch C. Is depression associated with dysfunction of the central reward system? Biochem Soc Trans. 2009 Feb;37(Pt 1):313-7. doi: 10.1042/BST0370313. PubMed 19143654 ↗
  • Salimpoor VN, Benovoy M, Larcher K, Dagher A, Zatorre RJ. Anatomically distinct dopamine release during anticipation and experience of peak emotion to music. Nat Neurosci. 2011 Feb;14(2):257-62. doi: 10.1038/nn.2726. Epub 2011 Jan 9. PubMed 21217764 ↗
  • Blood AJ, Zatorre RJ. Intensely pleasurable responses to music correlate with activity in brain regions implicated in reward and emotion. Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11818-23. doi: 10.1073/pnas.191355898. PubMed 11573015 ↗
  • Gold BP, Mas-Herrero E, Zeighami Y, Benovoy M, Dagher A, Zatorre RJ. Musical reward prediction errors engage the nucleus accumbens and motivate learning. Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):3310-3315. doi: 10.1073/pnas.1809855116. Epub 2019 Feb 6. PubMed 30728301 ↗
  • Menon V, Levitin DJ. The rewards of music listening: response and physiological connectivity of the mesolimbic system. Neuroimage. 2005 Oct 15;28(1):175-84. doi: 10.1016/j.neuroimage.2005.05.053. Epub 2005 Jul 14. PubMed 16023376 ↗
  • Ferreri L, Mas-Herrero E, Zatorre RJ, Ripolles P, Gomez-Andres A, Alicart H, Olive G, Marco-Pallares J, Antonijoan RM, Valle M, Riba J, Rodriguez-Fornells A. Dopamine modulates the reward experiences elicited by music. Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3793-3798. doi: 10.1073/pnas.1811878116. Epub 2019 Jan 22. PubMed 30670642 ↗
  • Ferreri L, Mas-Herrero E, Cardona G, Zatorre RJ, Antonijoan RM, Valle M, Riba J, Ripolles P, Rodriguez-Fornells A. Dopamine modulations of reward-driven music memory consolidation. Ann N Y Acad Sci. 2021 Oct;1502(1):85-98. doi: 10.1111/nyas.14656. Epub 2021 Jul 11. PubMed 34247392 ↗
  • Salimpoor VN, van den Bosch I, Kovacevic N, McIntosh AR, Dagher A, Zatorre RJ. Interactions between the nucleus accumbens and auditory cortices predict music reward value. Science. 2013 Apr 12;340(6129):216-9. doi: 10.1126/science.1231059. PubMed 23580531 ↗
  • Belfi AM, Loui P. Musical anhedonia and rewards of music listening: current advances and a proposed model. Ann N Y Acad Sci. 2020 Mar;1464(1):99-114. doi: 10.1111/nyas.14241. Epub 2019 Sep 23. PubMed 31549425 ↗
  • Zatorre RJ. Why Do We Love Music? Cerebrum. 2018 Nov 1;2018:cer-16-18. eCollection 2018 Nov-Dec. PubMed 30746026 ↗
  • Berridge KC, Kringelbach ML. Affective neuroscience of pleasure: reward in humans and animals. Psychopharmacology (Berl). 2008 Aug;199(3):457-80. doi: 10.1007/s00213-008-1099-6. Epub 2008 Mar 3. PubMed 18311558 ↗
  • Berridge KC, Robinson TE. Liking, wanting, and the incentive-sensitization theory of addiction. Am Psychol. 2016 Nov;71(8):670-679. doi: 10.1037/amp0000059. PubMed 27977239 ↗
  • Husain M, Roiser JP. Neuroscience of apathy and anhedonia: a transdiagnostic approach. Nat Rev Neurosci. 2018 Aug;19(8):470-484. doi: 10.1038/s41583-018-0029-9. PubMed 29946157 ↗
  • Ducharme S, Price BH, Dickerson BC. Apathy: a neurocircuitry model based on frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2018 Apr;89(4):389-396. doi: 10.1136/jnnp-2017-316277. Epub 2017 Oct 24. PubMed 29066518 ↗
  • Salimpoor VN, Benovoy M, Longo G, Cooperstock JR, Zatorre RJ. The rewarding aspects of music listening are related to degree of emotional arousal. PLoS One. 2009 Oct 16;4(10):e7487. doi: 10.1371/journal.pone.0007487. PubMed 19834599 ↗
  • Yang M, He H, Duan M, Chen X, Chang X, Lai Y, Li J, Liu T, Luo C, Yao D. The Effects of Music Intervention on Functional Connectivity Strength of the Brain in Schizophrenia. Neural Plast. 2018 May 2;2018:2821832. doi: 10.1155/2018/2821832. eCollection 2018. PubMed 29853841 ↗
  • Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1992 Spring;4(2):134-9. doi: 10.1176/jnp.4.2.134. PubMed 1627973 ↗
  • Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988 Jun;54(6):1063-70. doi: 10.1037//0022-3514.54.6.1063. PubMed 3397865 ↗
  • Tinaz S, Kamel S, Aravala SS, Sezgin M, Elfil M, Sinha R. Distinct neural circuits are associated with subclinical neuropsychiatric symptoms in Parkinson's disease. J Neurol Sci. 2021 Apr 15;423:117365. doi: 10.1016/j.jns.2021.117365. Epub 2021 Feb 21. PubMed 33636663 ↗
  • Smith CR, Cavanagh J, Sheridan M, Grosset KA, Cullen B, Grosset DG. Factor structure of the Montreal Cognitive Assessment in Parkinson disease. Int J Geriatr Psychiatry. 2020 Feb;35(2):188-194. doi: 10.1002/gps.5234. Epub 2019 Dec 3. PubMed 31736141 ↗
  • Richter P, Werner J, Heerlein A, Kraus A, Sauer H. On the validity of the Beck Depression Inventory. A review. Psychopathology. 1998;31(3):160-8. doi: 10.1159/000066239. PubMed 9636945 ↗
  • Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry. 1995 Jul;167(1):99-103. doi: 10.1192/bjp.167.1.99. PubMed 7551619 ↗
  • Nunes-Silva M, Haase VG. Montreal Battery of Evaluation of Amusia: Validity evidence and norms for adolescents in Belo Horizonte, Minas Gerais, Brazil. Dement Neuropsychol. 2012 Oct-Dec;6(4):244-252. doi: 10.1590/S1980-57642012DN06040008. PubMed 29213804 ↗
  • Burckhardt CS, Anderson KL. The Quality of Life Scale (QOLS): reliability, validity, and utilization. Health Qual Life Outcomes. 2003 Oct 23;1:60. doi: 10.1186/1477-7525-1-60. PubMed 14613562 ↗
  • Zhang Y, Zhang GY, Zhang ZE, He AQ, Gan J, Liu Z. White matter hyperintensities: a marker for apathy in Parkinson's disease without dementia? Ann Clin Transl Neurol. 2020 Sep;7(9):1692-1701. doi: 10.1002/acn3.51159. Epub 2020 Aug 28. PubMed 32857484 ↗
  • Martinez-Molina N, Mas-Herrero E, Rodriguez-Fornells A, Zatorre RJ, Marco-Pallares J. White Matter Microstructure Reflects Individual Differences in Music Reward Sensitivity. J Neurosci. 2019 Jun 19;39(25):5018-5027. doi: 10.1523/JNEUROSCI.2020-18.2019. Epub 2019 Apr 18. PubMed 31000588 ↗
  • Loui P, Patterson S, Sachs ME, Leung Y, Zeng T, Przysinda E. White Matter Correlates of Musical Anhedonia: Implications for Evolution of Music. Front Psychol. 2017 Sep 25;8:1664. doi: 10.3389/fpsyg.2017.01664. eCollection 2017. PubMed 28993748 ↗
  • Chomiak T, Watts A, Meyer N, Pereira FV, Hu B. A training approach to improve stepping automaticity while dual-tasking in Parkinson's disease: A prospective pilot study. Medicine (Baltimore). 2017 Feb;96(5):e5934. doi: 10.1097/MD.0000000000005934. PubMed 28151878 ↗
  • Zhu M, HajiHosseini A, Baumeister TR, Garg S, Appel-Cresswell S, McKeown MJ. Altered EEG alpha and theta oscillations characterize apathy in Parkinson's disease during incentivized movement. Neuroimage Clin. 2019;23:101922. doi: 10.1016/j.nicl.2019.101922. Epub 2019 Jul 2. PubMed 31284232 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Jul 2026, 53 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 53 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2022
First posted
Aug 17, 2022
StartActual
Feb 9, 2022
Primary completionEst.
Jul 31, 2026
CompletionEst.
Jul 31, 2026
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05505019
Collaborators
Northeastern University
Responsible party
Silke Cresswell (Principal Investigator, University of British Columbia) — Principal investigator
First posted
Aug 17, 2022
Start date
Feb 9, 2022
Primary completion
Jul 31, 2026 (estimated)
Completion
Jul 31, 2026 (estimated)
Last update
Mar 23, 2026

Study contacts

Mikey Jose, B.Sc.
Contact
miguel.jose@ubc.ca
(604) 822-3177
Annie Kuan
Contact
annie.kuan@ubc.ca
604-827-0576

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion